| Followers | 45 |
| Posts | 129 |
| Boards Moderated | 0 |
| Alias Born | 03/02/2021 |
Wednesday, January 15, 2025 11:05:09 AM
- Average time between first CHM meeting and approval for medicines that appear to have had their first CHM meeting in H1 2024 AND have already been approved: 6.43 months
- Knocking off high and low outliers, average approval time is 6.2 months, with a range of 5 months to 8 months.
- DCVax-L's meeting was at the end of June 2024. Therefore, it would be reasonable to expect approval between December 2024 and February 2025.
- With an average duration of 6.2 - 6.43 months from the first CHM meeting to approval, we would be looking at the middle of that range: mid-January 2025, i.e. right now.
This mostly coincides with the earlier window I proposed, with the exception that the end-of-February target is specifically based on the MHRA's recent performance with other medicines this year, whereas the earlier end-of-January target was based on the predicted date by which they would have completely cleared their backlog and gotten back on track to hitting statutory timelines.
Given that MHRA has now announced that the backlog has been cleared, and that there are at most 2 other drugs ahead of DCVax-L in the pipeline, I still feel good about my suggestion.
One caveat is that, assuming the other 2 drugs (mRESVIA and gallium-68 gozetotide) were approved this month, the average time from first CHM meeting to approval would rise to 7.14 - 7.2 months. That would push DCVax-L's likely approval (based on recent averages) into early February. But at that point, there would also be 0 medicines ahead of us in line...
This is all my personal opinion of course, based on analysis of the available data.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
